<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01751386</url>
  </required_header>
  <id_info>
    <org_study_id>130040</org_study_id>
    <secondary_id>13-AA-0040</secondary_id>
    <nct_id>NCT01751386</nct_id>
  </id_info>
  <brief_title>Baclofen for Treating Anxiety and Alcoholism</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Randomized Human Laboratory Pilot Study of Baclofen in Anxious Alcoholics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

      - Baclofen is a drug used to control muscle stiffness in people with neurological diseases.
      Some studies suggest that baclofen may reduce alcohol craving and use. It helps to reduce
      anxiety in alcoholics, which in turn can help to reduce cravings. Researchers want to see if
      baclofen can be a safe and effective treatment for alcoholics who have high anxiety levels.

      Objectives:

      - To see if baclofen is safe and helpful for people who have alcoholism and high anxiety
      levels.

      Eligibility:

        -  Individuals between 21 and 65 years of age who have been diagnosed with alcoholism and
           anxiety issues.

        -  Participants must not be taking anti-anxiety medication.

      Design:

        -  Participants will be screened with a physical exam and medical history. Blood and urine
           samples will be collected. Tests of alcohol dependency and anxiety levels will also be
           given.

        -  Participants will be divided into two groups. One group will take baclofen. The other
           group will have a placebo.

        -  About 1 week after the screening visit, participants will have a study visit. They will
           answer questions about their behavior and mood. They will then start to take either
           baclofen or a placebo. Participants will take the study drug three times a day, every
           day.

        -  After 1 week on the study drug, participants will have an overnight stay at the National
           Institutes of Health. They will have blood tests and answer questions about mood and
           behavior. They will also have tests that involve choosing to drink alcohol and answering
           more questions about cravings.

        -  Participants will stop taking their study drug over a 3-day period.

        -  A final follow-up visit will be required 1 week after the overnight study visit.
           Participants will receive information about other alcohol abuse treatment programs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective:

      The selective GABAB receptor agonist baclofen has been identified as a possible medication
      able to reduce alcohol craving and intake in alcohol dependent individuals. In keeping with
      several preclinical studies, most of the clinical studies have demonstrated baclofen s
      effects in reducing alcohol craving and intake and promoting alcohol abstinence. However, one
      trial with alcoholics with a low severity of dependence found a robust treatment effect, but
      no differences between baclofen and placebo. The inconsistency of baclofen s effects on
      alcohol drinking among previous treatment trials suggests that different AD individuals may
      respond differently to baclofen. Baclofen has been demonstrated to consistently reduce
      anxiety in alcoholic patients, and analyses of positive vs. null findings with baclofen
      suggest that alcoholic patients with higher levels of anxiety at baseline may represent a
      sub-population particularly responsive to baclofen treatment. Therefore, this study will
      systematically test, for the first time, the specific role of baclofen on alcohol-related
      outcomes in alcoholic individuals with high anxiety levels. Furthermore, the biobehavioral
      mechanisms by which baclofen reduces drinking are not well characterized. A human laboratory
      pilot study conducted at Brown University with non-treatment seeking alcohol-dependent
      individuals suggests that baclofen reduces alcohol consumption both in the naturalistic
      environment as well as in a well-controlled lab setting (using an alcohol self-administration
      [ASA] paradigm) and that this could be mediated by baclofen s ability to alter
      alcohol-related biphasic effects. An exploratory analysis also revealed that specific genetic
      polymorphisms might moderate baclofen s effects, i.e. DRD4 and 5HTTLPR polymorphisms,
      although the sample of that pilot study was very small to allow one to draft definitive
      conclusions. The present project proposes investigating baclofen using a design similar to
      that used in the previous pilot study (thus, an already validated paradigm), thus
      representing not only the first study testing baclofen in alcoholic individuals with high
      anxiety levels, but also the first study investigating baclofen s biobehavioral mechanisms in
      such a population for which baclofen may hypothetically show a very robust effect.

      Study population:

      Non-treatment seeking alcohol-dependent males and females with high anxiety levels.

      Design:

      The experimental design is a between-subject randomized double-blind controlled study. The
      medication conditions baclofen t.i.d. or placebo represent the between subjects factor. Each
      participant will be randomly assigned to one of the two medication conditions and will
      receive eight days of the medication, followed by an alcohol laboratory session on Day 8. The
      alcohol laboratory session will be conducted in a bar-like room in the NIAAA Outpatient
      Clinic of the NIH CRC. The study will be conducted in consecutive phases which will appear
      contiguous to volunteers: (1) a one-week screening period; (2) an 8-day period (+ 1-5 days if
      needed to permit some participants flexibility in scheduling the laboratory session) during
      which participants will take the study medication; (3) an alcohol laboratory session,
      including a cue reactivity (CR) test and an alcohol self-administration (ASA) procedure on
      Day 8 (last day at the target dose); (4) a 3-day period during which participants will
      undergo a dose reduction of the study medication; (5) a 1-week follow-up (including the
      tapering phase).

      Outcome measures:

      Alcohol drinking during the ASA will be measured as the primary outcome. Secondary objectives
      include baclofen s effects on alcohol cue-induced responses (urge to drink, attention to
      cues, blood pressure, heart rate, saliva), on the subjective effects of alcohol and on
      anxiety levels. We will also explore the role of possible moderators of baclofen s effects,
      namely family history of alcoholism, early vs. later onset of alcoholism, pre-treatment
      anxiety levels and genetic moderators (DRD4, 5-HTTPRL). This study does not offer direct
      benefit to participants but is likely to yield generalizable knowledge about the possible
      role of baclofen in treating alcoholic individuals with high anxiety levels. This will
      markedly facilitate the identification of a novel pharmacotherapy, thus facilitating the
      development of novel alcoholism treatments.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 3, 2012</start_date>
  <completion_date type="Actual">August 17, 2016</completion_date>
  <primary_completion_date type="Actual">August 17, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Amount of Alcohol Consumed During the Alcohol Self Administration (ASA) Session</measure>
    <time_frame>2 hours</time_frame>
    <description>Amount of alcohol was measured as the number of mini-drinks each participant decided to drink (0-8 mini-drinks). The alcohol content of each mini-drink was calculated based on the participants' total body water, and was designed to raise the blood alcohol concentration by 0.015 g/dL.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Alcoholism</condition>
  <condition>Alcohol Dependence</condition>
  <condition>Alcohol Drinking Related Problems</condition>
  <condition>Alcohol Drinking</condition>
  <condition>Anxiety Disorder</condition>
  <arm_group>
    <arm_group_label>Baclofen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baclofen 10 mg t.i.d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo t.i.d.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baclofen</intervention_name>
    <arm_group_label>Baclofen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

          -  Must be male or female between 21 and 65 years old (inclusive).

          -  Participants must meet criteria for current DSM-IV-TR diagnosis of alcohol dependence,
             supported by the Structured Clinical Interview for DSM-IV-TR Axis I Disorders (SCID).

          -  Participants must have a Trait STAI &gt; 39.

          -  Participants must be in good health as confirmed by medical history, physical
             examination, ECG, blood/urine lab tests.

          -  Females must be postmenopausal for at least one year, surgically sterile, or
             practicing an effective method of birth control before entry and throughout the study;
             have a negative urine pregnancy test at each visit. Reliable methods of birth control
             include oral contraceptives or Norplant ; barrier methods such as diaphragms with
             contraceptive jelly, cervical caps with contraceptive jelly, condoms with
             contraceptive foam, or intrauterine devices; a partner with a vasectomy; or abstinence
             from intercourse.

        EXCLUSION CRITERIA:

          -  Individuals expressing interest in treatment for alcoholism and/or anxiety.

          -  Pregnancy or breast feeding women or not using an adequate form of birth control

          -  Unable to provide a negative urine drug screen.

          -  Individuals diagnosed with a current substance dependence diagnosis, other than
             alcohol or nicotine.

          -  Meet DSM-IV Axis I criteria for a lifetime diagnosis of schizophrenia, bipolar
             disorder, or other psychoses.

          -  An active illness within the past 6 months of Visit 1 that meet the DSM-IV criteria
             for a diagnosis of Major Depressive Disorder (MDD). Subjects with a history of
             attempted suicide will be excluded.

          -  Clinically significant medical abnormalities (i.e., unstable hypertension, clinically
             significant ECG abnormalities, Creatinine greater than or equal to 2 mg/dL). Although
             baclofen has demonstrated a safe profile when administered to alcoholic individuals
             with liver cirrhosis, including those with Hepatitis C, this study employs the oral
             administration of alcohol. Therefore, individuals with clinically significant liver
             problems will be excluded, i.e. liver cirrhosis, AST or ALT &gt; 5 times the upper normal
             limit (UNL), and individuals with Hepatitis B and C.

          -  Current use of psychotropic medications that cannot be discontinued and that may have
             an effect on alcohol consumption (thus confounding the results of the study) or that
             may interact with baclofen. Specifically, contraindicated medications will include:
             naltrexone, acamprosate, alcohol dehydrogenase inhibitors, topiramate, gabapentin,
             ondansetron, benzodiazepines, beta-blockers, H2-blockers, and alpha-1 blockers.

          -  Medical contraindications for use of baclofen.

          -  A history of adverse reaction or hypersensitivity to baclofen.

          -  Participants who have significant alcohol withdrawal symptoms, defined as a CIWA-Ar &gt;
             8.

          -  History of epilepsy or alcohol-related seizures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lorenzo Leggio, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2013-AA-0040.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Addolorato G, Abenavoli L, Leggio L, Gasbarrini G. How many cravings? Pharmacological aspects of craving treatment in alcohol addiction: a review. Neuropsychobiology. 2005;51(2):59-66. Epub 2005 Feb 28. Review.</citation>
    <PMID>15741745</PMID>
  </reference>
  <reference>
    <citation>Addolorato G, Caputo F, Capristo E, Domenicali M, Bernardi M, Janiri L, Agabio R, Colombo G, Gessa GL, Gasbarrini G. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol. 2002 Sep-Oct;37(5):504-8.</citation>
    <PMID>12217947</PMID>
  </reference>
  <reference>
    <citation>Addolorato G, Caputo F, Capristo E, Janiri L, Bernardi M, Agabio R, Colombo G, Gessa GL, Gasbarrini G. Rapid suppression of alcohol withdrawal syndrome by baclofen. Am J Med. 2002 Feb 15;112(3):226-9.</citation>
    <PMID>11893350</PMID>
  </reference>
  <reference>
    <citation>Leggio L, Zywiak WH, Edwards SM, Tidey JW, Swift RM, Kenna GA. A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers. Psychopharmacology (Berl). 2015 Jan;232(1):233-43. doi: 10.1007/s00213-014-3652-9. Epub 2014 Jun 29. Erratum in: Psychopharmacology (Berl). 2015 May;232(9):1667.</citation>
    <PMID>24973894</PMID>
  </reference>
  <reference>
    <citation>Leggio L, Zywiak WH, McGeary JE, Edwards S, Fricchione SR, Shoaff JR, Addolorato G, Swift RM, Kenna GA. A human laboratory pilot study with baclofen in alcoholic individuals. Pharmacol Biochem Behav. 2013 Feb;103(4):784-91. doi: 10.1016/j.pbb.2012.11.013. Epub 2012 Dec 19.</citation>
    <PMID>23262301</PMID>
  </reference>
  <reference>
    <citation>Leggio L, Ferrulli A, Zambon A, Caputo F, Kenna GA, Swift RM, Addolorato G. Baclofen promotes alcohol abstinence in alcohol dependent cirrhotic patients with hepatitis C virus (HCV) infection. Addict Behav. 2012 Apr;37(4):561-4. doi: 10.1016/j.addbeh.2011.12.010. Epub 2011 Dec 27.</citation>
    <PMID>22244707</PMID>
  </reference>
  <results_reference>
    <citation>Farokhnia M, Schwandt ML, Lee MR, Bollinger JW, Farinelli LA, Amodio JP, Sewell L, Lionetti TA, Spero DE, Leggio L. Biobehavioral effects of baclofen in anxious alcohol-dependent individuals: a randomized, double-blind, placebo-controlled, laboratory study. Transl Psychiatry. 2017 Apr 25;7(4):e1108. doi: 10.1038/tp.2017.71.</citation>
    <PMID>28440812</PMID>
  </results_reference>
  <verification_date>July 17, 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2012</study_first_submitted>
  <study_first_submitted_qc>December 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2012</study_first_posted>
  <results_first_submitted>July 17, 2017</results_first_submitted>
  <results_first_submitted_qc>July 17, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 16, 2017</results_first_posted>
  <last_update_submitted>August 18, 2017</last_update_submitted>
  <last_update_submitted_qc>August 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Addiction</keyword>
  <keyword>Cue-Induced Craving</keyword>
  <keyword>Craving</keyword>
  <keyword>Anxiety</keyword>
  <keyword>Alcohol Consumption</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The NIH Biomedical Translational Research Information System</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Baclofen</title>
          <description>Baclofen capsules: 15 mg/day (5 mg t.i.d.; titration phase) for 3 days, followed by 30 mg/day (10 mg t.i.d.; target dose) until the alcohol laboratory session; then, 15 mg/day (5 mg t.i.d.; taper down) for three additional days.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo capsules, similar to baclofen in appearance, texture, taste, and odor</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Baclofen</title>
          <description>Baclofen capsules: 15 mg/day (5 mg t.i.d.; titration phase) for 3 days, followed by 30 mg/day (10 mg t.i.d.; target dose) until the alcohol laboratory session; then, 15 mg/day (5 mg t.i.d.; taper down) for three additional days.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo capsules, similar to baclofen in appearance, texture, taste, and odor</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Amount of Alcohol Consumed During the Alcohol Self Administration (ASA) Session</title>
        <description>Amount of alcohol was measured as the number of mini-drinks each participant decided to drink (0-8 mini-drinks). The alcohol content of each mini-drink was calculated based on the participants' total body water, and was designed to raise the blood alcohol concentration by 0.015 g/dL.</description>
        <time_frame>2 hours</time_frame>
        <population>The analysis included all subjects who took the medication (either baclofen or placebo) and finished the alcohol laboratory session</population>
        <group_list>
          <group group_id="O1">
            <title>Baclofen</title>
            <description>Baclofen capsules: 15 mg/day (5 mg t.i.d.; titration phase) for 3 days, followed by 30 mg/day (10 mg t.i.d.; target dose) until the alcohol laboratory session; then, 15 mg/day (5 mg t.i.d.; taper down) for three additional days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo capsules, similar to baclofen in appearance, texture, taste, and odor</description>
          </group>
        </group_list>
        <measure>
          <title>Total Amount of Alcohol Consumed During the Alcohol Self Administration (ASA) Session</title>
          <description>Amount of alcohol was measured as the number of mini-drinks each participant decided to drink (0-8 mini-drinks). The alcohol content of each mini-drink was calculated based on the participants' total body water, and was designed to raise the blood alcohol concentration by 0.015 g/dL.</description>
          <population>The analysis included all subjects who took the medication (either baclofen or placebo) and finished the alcohol laboratory session</population>
          <units>mini-drinks</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.11" spread="0.66"/>
                    <measurement group_id="O2" value="4.5" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>15 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Baclofen</title>
          <description>Baclofen capsules: 15 mg/day (5 mg t.i.d.; titration phase) for 3 days, followed by 30 mg/day (10 mg t.i.d.; target dose) until the alcohol laboratory session; then, 15 mg/day (5 mg t.i.d.; taper down) for three additional days.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo capsules, similar to baclofen in appearance, texture, taste, and odor</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lorenzo Leggio</name_or_title>
      <organization>National Institute on Alcohol Abuse and Alcoholism</organization>
      <phone>+1 301 435 9398</phone>
      <email>lorenzo.leggio@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

